Safety Assessment
hematologic disease, rash, fever, anaphylactic shock
ADVERSE EVENT, HEMATOLOGIC DISEASE, ANAPHYLACTIC SHOCK, HEART ATTACK
The Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 in blood and hematologic disease was considered for safety assessment analysis. The CTCAE parameters based on clinical symptoms and vital signs were listed as heart attack, changes in respiratory capacity, fever, rash, and anaphylactic shock symptoms that were checked using remote patient monitoring (RPM) devices during cell infusion until 48 h. The patient ’s vital signs, laboratory readings, and physical recovery progress were closely monitored, recorded in their medical files, and graded using the CTCEA checklist (Supplementary file 